SP
TEVA icon

Symmetry Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Symmetry Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-706
Closed -$23K – 57
2017
Q1 		$23K Buy
+706
New +$24.1K 0.01% 51

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Symmetry Partners's TEVA Position: Q2 2017 in Review

Symmetry Partners sold out of Teva Pharmaceuticals (TEVA) in Q2 2017, closing a stake of 706 shares — an estimated $23K sold.

Symmetry Partners first reported a position in TEVA in Q1 2017 and held it in 1 quarter. The position peaked at $23K in Q1 2017. 648 funds tracked by Wall St. Rank hold TEVA as of Q2 2017.

  • Symmetry Partners reported no remaining Teva Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Symmetry Partners sold 706 Teva Pharmaceuticals shares in Q2 2017, an estimated $23K.
  • Symmetry Partners first reported a position in Teva Pharmaceuticals in Q1 2017 and held it in 1 quarter.
  • Symmetry Partners's Teva Pharmaceuticals position peaked at $23K in Q1 2017.
  • 648 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2017.

Based on Symmetry Partners's 13F filing for Q2 2017, filed 2 Aug 2017.